HAK11 Antibody

What is the HA.11 epitope tag and how does it differ from other epitope tags?

The HA.11 epitope tag is derived from the human influenza hemagglutinin surface glycoprotein, specifically corresponding to amino acids 98-106 with the sequence YPYDVPDYA . Unlike other common epitope tags such as FLAG or Myc, HA.11 represents a second-generation antibody that offers improved specificity over the original 12CA5 monoclonal antibody . The key advantage of the HA.11 antibody is its ability to recognize the HA epitope regardless of its position within the protein sequence—whether at the N-terminus, C-terminus, or internal locations—making it exceptionally versatile for protein tagging strategies .

How should the HA.11 antibody be stored and handled to maintain its activity?

The HA.11 antibody should be stored at -20°C to preserve its functionality . Upon initial thawing, it is critical to divide the antibody into working aliquots before returning them to -20°C storage . Multiple freeze-thaw cycles should be strictly avoided as they can lead to protein denaturation and subsequent loss of antibody activity . The antibody is typically supplied as undiluted crude mouse ascites fluid with an estimated concentration between 1-3 mg/mL, though this may vary between production lots .

What are the most reliable positive controls for validating HA.11 antibody specificity?

The use of appropriate positive controls is essential for validating HA.11 antibody specificity in experimental setups. The Posi-Tag Control Protein (product #931301) is specifically recommended as a reliable positive control for HA.11 antibody detection . Additionally, researchers can generate control vectors expressing known proteins tagged with the HA epitope (YPYDVPDYA sequence) to verify antibody performance in their specific experimental systems . Including non-tagged control samples is equally important to confirm the absence of non-specific binding.

How can HA.11 antibody be utilized in immunoprecipitation followed by mass spectrometry for identifying protein interactions?

For IP-MS applications, the HA.11 antibody has demonstrated exceptional performance due to its high specificity . The methodology involves: (1) Lysing cells expressing HA-tagged proteins under conditions that preserve protein-protein interactions (typically using buffers containing 0.5% NP-40 or 1% Triton X-100); (2) Pre-clearing lysates with protein G beads to reduce non-specific binding; (3) Incubating cleared lysates with HA.11 antibody at a 1:150 dilution overnight at 4°C; (4) Capturing antibody-antigen complexes with protein G beads; (5) Performing stringent washing steps to remove non-specific interactions; (6) Eluting bound proteins either with SDS sample buffer for direct analysis or with HA peptide for native elution; and (7) Processing eluates for mass spectrometry analysis. This approach has been successfully employed in numerous studies, including work by Pashkova et al. (2016) and Zhang et al. (2016), who identified novel protein interaction networks .

What strategies can overcome epitope masking when the HA tag is inaccessible in folded proteins?

Epitope masking represents a significant challenge when the HA tag becomes buried or structurally inaccessible in the folded protein. Advanced strategies to address this include: (1) Testing alternative tag positions (N-terminal versus C-terminal or internal positioning); (2) Incorporating flexible linker sequences (such as Gly-Ser repeats) between the tag and the protein of interest to improve accessibility; (3) Employing denaturing conditions selectively during detection steps for applications like Western blotting; (4) Using multiple tandem repeats of the HA tag to increase avidity and detection sensitivity; and (5) Considering dual-tagging approaches where a secondary tag (like FLAG or Myc) is incorporated to provide alternative detection options. Researchers should conduct pilot experiments with different tagging strategies when working with structurally complex proteins or membrane-embedded domains.

How can the HA.11 antibody be employed in chromatin immunoprecipitation (ChIP) assays for studying protein-DNA interactions?

The HA.11 antibody has been successfully used in ChIP applications to study transcription factors and chromatin-modifying enzymes . The optimized protocol involves: (1) Crosslinking protein-DNA complexes in intact cells with 1% formaldehyde for 10 minutes; (2) Sonicating chromatin to fragments of approximately 200-500 bp; (3) Immunoprecipitating with HA.11 antibody at a 1:200 dilution; (4) Utilizing magnetic protein G beads for capturing complexes; (5) Performing sequential washes with increasing stringency buffers; (6) Reversing crosslinks and purifying DNA; and (7) Analyzing enriched genomic regions by qPCR or sequencing. Crucially, researchers must include appropriate controls, such as input chromatin and immunoprecipitation with non-specific IgG. This approach has been successfully employed in studies by Mitxelena et al. (2016) investigating cell cycle-regulated transcription factors .

What are the considerations for using HA.11 antibody in multi-color immunofluorescence experiments with other epitope tags?

When designing multi-color immunofluorescence experiments incorporating HA.11 antibody alongside other epitope tag detection systems, researchers should address several critical factors: (1) Antibody cross-reactivity must be thoroughly tested using appropriate controls expressing single tags; (2) The selection of primary antibodies should consider host species compatibility to enable clear discrimination with secondary antibodies; (3) Sequential staining protocols may be necessary when using multiple mouse-derived primary antibodies; (4) Blocking steps should be optimized to minimize background signal; (5) Spectral compatibility of fluorophores must be carefully planned to minimize bleed-through; and (6) Appropriate negative controls for each antibody combination should be included. Studies by Lawson et al. (2016) have successfully employed these strategies to visualize multiple tagged proteins in complex cellular contexts .

How should researchers design HA-tagged fusion proteins to minimize interference with protein function?

Optimal design of HA-tagged fusion proteins requires careful consideration of several factors to preserve native protein function. The positioning of the HA tag (YPYDVPDYA) is critical—researchers should analyze protein structure data or make predictions to avoid disrupting functional domains, active sites, or protein-protein interaction interfaces . For proteins with known structures, computational modeling can help predict whether tag placement might cause steric hindrance. When structural information is unavailable, creating both N-terminal and C-terminal tagged versions for comparative functional assays is recommended. Additionally, incorporating flexible linker sequences (typically 2-5 Gly-Ser repeats) between the protein and the tag can minimize structural interference. Functional validation comparing the tagged protein to the untagged version is essential to confirm that biological activity is preserved.

What strategies can address weak signal detection when using the HA.11 antibody in Western blotting?

When encountering weak signal detection with HA.11 antibody in Western blotting, researchers can implement several optimization strategies: (1) Increase protein loading amounts to 50-80 μg per lane; (2) Extend primary antibody incubation to overnight at 4°C using a more concentrated antibody dilution (1:1000 instead of 1:5000); (3) Employ enhanced chemiluminescence (ECL) substrates with higher sensitivity; (4) Utilize signal amplification systems such as biotin-streptavidin; (5) Consider using PVDF membranes instead of nitrocellulose for higher protein retention; (6) Optimize transfer conditions, potentially using wet transfer methods for larger proteins; (7) Incorporate 0.1% SDS in the antibody dilution buffer to enhance accessibility of the epitope; and (8) Consider using mild detergents like 0.05% Tween-20 in washing buffers to reduce background while preserving specific signals .

How can researchers quantitatively assess the expression levels of HA-tagged proteins using flow cytometry?

Quantitative assessment of HA-tagged protein expression via flow cytometry requires careful experimental design and controls. The procedure involves: (1) Fixing cells with 2-4% paraformaldehyde followed by permeabilization with 0.1-0.5% saponin for intracellular proteins; (2) Blocking with 2-5% BSA in PBS; (3) Incubating with HA.11 antibody at 1:500-1:1000 dilution; (4) Using fluorophore-conjugated secondary antibodies appropriate for flow cytometry; (5) Including isotype control antibodies to set negative population gates; (6) Using calibration beads with known numbers of fluorophore molecules to establish a standard curve for quantification; and (7) Analyzing median fluorescence intensity (MFI) values to quantify relative expression levels . This approach enables researchers to compare expression levels across different constructs or experimental conditions, as demonstrated in studies examining MHC-peptide complex expression .

What are the common sources of background signal when using HA.11 antibody and how can they be mitigated?

Background signal when using HA.11 antibody can arise from multiple sources that require specific mitigation strategies: (1) Non-specific binding of primary antibody can be addressed by increasing the concentration of blocking agents (5% BSA or 10% normal serum) and extending blocking time to 1-2 hours; (2) Cross-reactivity with endogenous proteins can be assessed using non-transfected control samples and potentially addressed by pre-absorbing the antibody with cell lysates from negative control samples; (3) Insufficient washing can be resolved by increasing the number and duration of wash steps (5-6 washes of 5-10 minutes each); (4) Excessive antibody concentration should be corrected through careful titration experiments; (5) Sample overloading in Western blots can be addressed by reducing protein amounts; and (6) Fixation artifacts can be minimized by optimizing fixation conditions or testing alternative fixatives . The implementation of these strategies has been reported to significantly improve signal-to-noise ratios in studies by Lehmann et al. (2016) and Testoni et al. (2016) .

How can researchers distinguish between specific and non-specific binding when using HA.11 antibody in novel experimental systems?

Distinguishing specific from non-specific binding requires rigorous control experiments: (1) Include non-tagged/empty vector controls processed identically to HA-tagged samples; (2) Perform peptide competition assays where the antibody is pre-incubated with excess HA peptide (YPYDVPDYA) to block specific binding sites; (3) Compare results from multiple antibody dilutions, as specific signals typically remain at higher dilutions while background diminishes; (4) Validate results using alternative detection methods (e.g., comparing Western blot and immunofluorescence results); (5) When possible, use CRISPR-Cas9 knockout cell lines as negative controls; and (6) Consider using alternative anti-HA antibodies from different clones to confirm findings . Researchers should report these validation steps in publications to enhance reproducibility, as exemplified in studies by Guirouilh-Barbat et al. (2016) .

What strategies can overcome detection issues when the HA-tagged protein undergoes post-translational modifications?

Post-translational modifications (PTMs) can mask the HA epitope or alter antibody binding efficiency. To address these challenges: (1) For phosphorylation-sensitive detection, researchers should test both phosphatase-treated and untreated samples; (2) When glycosylation may interfere with detection, samples can be treated with appropriate deglycosylation enzymes prior to analysis; (3) For proteins subject to ubiquitination, proteasome inhibitors (MG132) can be used to stabilize modified forms; (4) In cases where the tag might be cleaved by proteases, protease inhibitor cocktails should be included during sample preparation; (5) For proteins with complex modification patterns, immunoprecipitation with HA.11 followed by detection with modification-specific antibodies can provide additional insights; and (6) Multiple tagging approaches (combining HA tag with other epitope tags) can help distinguish modification-dependent detection issues . These strategies have proven effective in studies investigating complex PTM patterns, as demonstrated by Yagita et al. (2017) .

How can the HA.11 antibody be effectively used in proximity ligation assays (PLA) to study protein-protein interactions?

The HA.11 antibody can be employed in proximity ligation assays to visualize and quantify protein-protein interactions with high specificity. The optimized protocol involves: (1) Expressing one protein with an HA tag and its potential interaction partner with a different tag (e.g., FLAG or Myc); (2) Fixing cells with 4% paraformaldehyde for 15 minutes and permeabilizing with 0.2% Triton X-100; (3) Blocking with Duolink blocking solution for 1 hour; (4) Co-incubating with HA.11 antibody (1:1000) and an antibody against the partner protein's tag; (5) Applying PLA probes against the respective primary antibodies; (6) Performing ligation and amplification according to manufacturer's protocols; and (7) Analyzing PLA signals using confocal microscopy or high-content imaging systems . This approach provides spatial information about protein interactions at single-molecule resolution and has been successfully implemented in studies by Avgousti et al. (2016) and Shin et al. (2015) .

How does the HA.11 antibody compare with other anti-HA antibodies in terms of sensitivity and specificity?

The HA.11 antibody (clone 16B12) offers several advantages over other anti-HA antibodies, particularly the first-generation 12CA5 clone. Comparative analysis reveals that HA.11 demonstrates approximately 2-3 fold higher sensitivity in Western blotting applications, with a detection limit of approximately 5-10 ng of tagged protein compared to 15-30 ng for 12CA5 . In immunoprecipitation assays, HA.11 typically recovers 70-85% of target proteins versus 50-65% for alternative clones . The critical advantage of HA.11 lies in its ability to recognize the epitope in various protein contexts—whether at termini or internal positions—while some alternative antibodies show position-dependent sensitivity . Furthermore, HA.11 exhibits minimal cross-reactivity with endogenous proteins in mammalian cell systems, making it suitable for applications requiring high specificity. These performance characteristics have made HA.11 the preferred choice for complex applications like ChIP-seq and proximity-dependent labeling techniques.

How can the HA.11 antibody be utilized in combination with BioID or APEX2 proximity labeling techniques?

The integration of HA.11 antibody detection with proximity labeling technologies enables powerful analyses of protein interaction networks and subcellular localization. For BioID applications, researchers can create fusion proteins containing both an HA tag and the BioID2 enzyme by: (1) Designing constructs with the minimal HA tag (YPYDVPDYA) positioned to avoid interference with BioID2 activity; (2) Expressing these constructs in cells and supplying biotin (50 μM) for 16-24 hours; (3) Lysing cells under stringent conditions (1% SDS) followed by dilution for streptavidin capture; (4) Confirming proper expression and localization of the fusion protein using HA.11 antibody detection via immunofluorescence or Western blotting; (5) Capturing biotinylated proteins with streptavidin beads; and (6) Analyzing specific interactors by mass spectrometry . This approach has been successfully employed by Davis et al. (2017) to map nuclear protein interactions . Similar strategies can be applied with APEX2-based proximity labeling, using HA detection to verify expression while leveraging the peroxidase activity for proximity mapping.

What are the considerations for using HA.11 antibody in live-cell imaging applications?

While traditional applications of HA.11 antibody involve fixed samples, advanced live-cell imaging approaches are possible with specific optimizations: (1) Use fluorescently-conjugated HA.11 antibody fragments (Fab fragments) that can penetrate the plasma membrane when combined with specialized delivery methods like bead loading or electroporation; (2) Consider expressing anti-HA single-chain antibodies fused to fluorescent proteins (intrabodies) that can bind HA-tagged proteins in living cells; (3) For cell surface proteins, membrane-impermeable HA.11 antibody can be applied directly to the medium (1:200-1:500 dilution) to label extracellular epitopes; (4) Minimize phototoxicity by using red-shifted fluorophores and reducing laser power during imaging; (5) Include appropriate controls to confirm specificity, such as untagged proteins or competition with soluble HA peptide; and (6) Consider the impact of antibody binding on protein dynamics and function, as binding may alter trafficking or interactions . These approaches have been used to track receptor dynamics in studies by Gong et al. (2017) .

How can the HA.11 antibody be leveraged in super-resolution microscopy techniques?

The application of HA.11 antibody in super-resolution microscopy requires specific adaptations to achieve optimal resolution and specificity: (1) For STORM/PALM imaging, use secondary antibodies conjugated to photoswitchable fluorophores like Alexa Fluor 647 or Cy5/Cy3 pairs; (2) For STED microscopy, employ secondary antibodies with STED-compatible fluorophores such as STAR635P or Abberior dyes; (3) Minimize the physical distance between the epitope and fluorophore by using directly-labeled primary antibodies or smaller detection probes like nanobodies when possible; (4) Implement sample clearing techniques (e.g., using mounting media with optimized refractive indices) to reduce background fluorescence; (5) Optimize fixation protocols to ensure structural preservation at nanoscale resolution, preferring glutaraldehyde for cytoskeletal proteins or specific mixtures for membrane proteins; and (6) Include fiducial markers for drift correction during extended imaging sessions . These approaches have enabled visualization of HA-tagged proteins with 20-30 nm resolution in studies by Stoeber et al. (2016) .

How can HA.11 antibody be utilized in CRISPR-based knock-in strategies for tagging endogenous proteins?

The HA.11 antibody can be leveraged effectively in CRISPR/Cas9 knock-in applications for detecting endogenously tagged proteins. The optimized workflow involves: (1) Designing guide RNAs targeting the intended insertion site (typically near the start or stop codon of the gene of interest); (2) Creating a donor template containing the minimal HA tag sequence (YPYDVPDYA) flanked by 500-800 bp homology arms; (3) Co-delivering Cas9, guide RNA, and donor template to cells via nucleofection or lipofection; (4) Screening for successful knock-in events using PCR across the insertion junctions; (5) Confirming proper expression using HA.11 antibody via Western blotting at 1:1000-1:2000 dilution; and (6) Validating correct localization and function of the tagged endogenous protein . This approach provides physiologically relevant expression levels compared to overexpression systems and has been successfully employed in studies by Aldrin-Kirk et al. (2016) for in vivo neuronal protein tagging .

What are the considerations for using HA.11 antibody in detecting protein-RNA interactions through techniques like CLIP-seq?

The HA.11 antibody can be effectively employed in Cross-Linking Immunoprecipitation sequencing (CLIP-seq) to study RNA-protein interactions when the RNA-binding protein is HA-tagged. The optimized protocol involves: (1) UV-crosslinking cells expressing HA-tagged RNA-binding proteins at 254 nm (400 mJ/cm²); (2) Lysing cells in stringent conditions containing RNase inhibitors; (3) Performing limited RNase digestion to reduce RNA fragments to 30-100 nucleotides; (4) Immunoprecipitating with HA.11 antibody at 1:150 dilution; (5) Including extensive washing steps with high-salt buffers to remove non-specific interactions; (6) Radiolabeling RNA fragments for visualization; (7) Size-selecting protein-RNA complexes; (8) Proteinase K digestion to release RNA; and (9) Preparing libraries for high-throughput sequencing . This approach has been successfully implemented by Piwko et al. (2016) to identify RNA interactions of DNA damage response proteins .

How can HA.11 antibody be incorporated into spatial proteomics approaches like proximity-dependent biotin identification?

Integrating HA.11 antibody detection with spatial proteomics techniques enables comprehensive mapping of protein interactomes within specific cellular compartments. For TurboID or miniTurbo applications (evolved BioID variants), researchers can: (1) Generate fusion constructs containing the HA epitope tag and TurboID/miniTurbo separated by a flexible linker; (2) Confirm proper expression and localization of the fusion protein using HA.11 immunofluorescence; (3) Activate proximity labeling with brief biotin exposure (10 minutes for TurboID versus 1 hour for BioID); (4) Validate the efficiency and specificity of biotinylation using streptavidin detection methods alongside HA.11 antibody detection; (5) Perform quantitative proteomics on streptavidin-purified proteins; and (6) Build interaction networks based on enriched proteins . This approach allows researchers to generate temporal and spatial maps of protein interactions with unprecedented resolution, as demonstrated in recent studies examining nuclear envelope proteins and signaling complexes .

What are the emerging applications of HA.11 antibody in detecting neoepitopes for cancer immunotherapy research?

The principles underlying HA epitope detection have emerging applications in cancer immunotherapy research, particularly in studying neoepitope presentation. For researchers investigating PIK3CA H1047L and similar mutations as potential immunotherapy targets, HA.11 antibody methodologies provide valuable insights: (1) The MHC peptide loading assay using TAP1-KO-A11+ K562 cells demonstrates principles similar to those used for validating neoepitope presentation, where cells are incubated with synthetic peptides and surface presentation is quantified ; (2) Flow cytometry approaches using HA.11 detection systems provide templates for measuring MHC-neoepitope complex expression levels on cancer cells ; (3) T cell activation assays employing HA.11-based detection systems offer parallels to methods for measuring neoantigen-specific T cell responses ; and (4) TCR engineering approaches developed for detecting HA-tagged proteins can inform similar strategies for neoepitope-specific TCR development . These methodological crossovers highlight how epitope tagging systems contribute to broader immunotherapeutic research applications.